GlassScriptPhysician profile
Carl Gibson
NPI 1003888264
$1,065.20
in general payments reported to CMS, 2019-2025
22 companies · $322 in 2025
The $322 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $290 · 2020: $67.60 · 2021: $64.08 · 2022: $23.47 · 2023: $93.38 · 2024: $205 · 2025: $322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $619.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insulet Corporation | $172.06 | 2019-2025 | Omnipod |
| Lilly USA, LLC | $134.06 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.86 | 2019-2025 | Jardiance |
| Dexcom, INC. | $74.12 | 2019-2024 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $57.31 | 2019-2021 | |
| Novo Nordisk INC | $57.02 | 2019-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $55.23 | 2019-2020 | |
| Beta Bionics, INC. | $52.30 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Xeris Pharmaceuticals, INC. | $47.26 | 2024-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $45.60 | 2019-2025 | Korlym |
| Amgen INC. | $38.91 | 2022-2025 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $34.04 | 2019-2020 | |
| Ascensia Diabetes Care US INC. | $27.95 | 2025 | |
| Radius Health, INC. | $26.76 | 2019-2020 | |
| Inspire Medical Systems, INC. | $25.68 | 2025 | Inspire |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $25.16 | 2019 | |
| Abbott Laboratories | $24.61 | 2024 | Freestyle Libre 3 |
| Sanofi US Services INC. | $24.11 | 2023 | |
| Mannkind Corporation | $18.87 | 2024 | |
| Shire North American Group INC | $17.36 | 2019 | |
| Abbvie INC. | $14.04 | 2024 | |
| Amneal Pharmaceuticals LLC | $10.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carl Gibson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.